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INTRODUCTION 
 
 
 
 
 
1. INTRODUCTION 
Chronic Kidney Disease (CKD) is an international public health problem affecting 
about 5–10% of the population. As kidney function declines, there is a progressive 
deterioration in mineral homeostasis with disruption of normal serum concentrations of 
phosphorus, calcium and changes in circulating levels of hormones like parathyroid hormone 
(PTH) and Vitamin D3. Beginning in CKD stage 3, the ability of the kidneys to appropriately 
excrete phosphorous load is diminished, leading to hyperphosphatemia. Kid neys fail to 
respond adequately to PTH, which normally promotes calcium reabsorption and phosphorus 
excretion. In addition, there is a down regulation of vitamin D receptor and resistance to the 
actions of PTH at tissue level causing secondary hyperparathyroidism. (1) 
 
Hyperparathyroidism plays a vital role in the excess morbidity and mortality in 
chronic kidney disease. As a result; patients are at increased risk of bone disease, extra 
osseous calcification, and death. (1) These changes probably begin early in the course of 
CKD, when Glomerular Filtration Rate (GFR) declines below 60 mL/min per 1.73 m2. (2) 
 
Cardiovascular disease accounts for 70% of all deaths in patients with CKD, with an 
overall mortality of 20% per year in patients on dialysis. (3) Left Ventricular Hypertrophy 
(LVH) is the most prevalent cardiac complication observed in CKD patients and is often 
associated with myocardial fibrosis, poor perfusion, and cell death. Hyperphosphatemia and 
hypercalcemia have been shown to promote calcification of the vasculature, myocardium, 
and cardiac valves. Vascular calcification, manifested in reduced vessel wall elasticity, 
increased intima media layer thickness is linked to LVH, and occurs with increased severity 
in dialysis patients versus non-CKD patients. (4) Vascular and soft-tissue calcifications are 
strong predicators of cardiovascular mortality among CKD patients.  
Clinical care guidelines suggest that, at least annual testing and subsequent treatment 
of disorders of bone and mineral metabolism is essential early in the course of CKD when 
GFR is still 60 ml/min per 1.73 m2. But various investigations suggest that less than 25% of 
patients reach the target levels for intact parathyroid hormone (PTH) measurement or     
control. (5) 
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2. AIM & OBJECTIVES 
 
1. To correlate serum intact parathyroid hormone, urea, creatinine, calcium,  
phosphorus and alkaline phosphatase in various stages of CKD and to compare the same with 
the control group. 
 
2. To find the role of intact parathyroid hormone in the early diagnosis of mineral 
disturbances in CKD patients. 
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3. REVIEW OF LITERATURE 
CHRONIC KIDNEY DISEASE: 
Kidney - Anatomy 
A kidney is a reddish brown, bean-shaped organ with a smooth surface. In an adult, it 
is about 12 centimetres long, 6 centimetres wide and 3 centimetres thick, and it is enclosed  in 
a tough, fibrous capsule tunica fibrosa.  
Location of the Kidneys 
The kidneys lie on either side of the vertebral column, the upper and lower borders of 
the kidneys are generally at the levels of the twelfth thoracic and third lumbar vertebrae, 
respectively, although the positions of the kidneys may vary slightly with changes in posture 
and with breathing movements. The left kidney is usually about 1.5 to 2 centimetres higher 
than the right one. 
 
Fig 1: Location of kidney 
 
Kidney Structure  
The lateral surface of each kidney is convex, but its medial side is deeply concave. 
The resulting medial depression leads into a hollow chamber called the renal sinus. Through 
the entrance to this sinus pass blood vessels, nerves, lymphatic vessels and the ureter .The  
superior end of the ureter expands to form a funnel-shaped sac called the renal pelvis, which 
is located inside the renal sinus. 
The pelvis is subdivided into two or three tubes called major calyces and they in turn 
are subdivided into eight to fourteen minor calyces. A series of small projections called renal 
papillae project into each minor calyx. The kidney includes two distinct regions: an inner 
medulla and an outer cortex. The renal medulla is composed of conical masses of tissue  
called renal pyramids, the bases of which are directed toward the convex surface of the  
kidney, and the apexes of which form the renal papillae. The tissue of the medulla appears 
striated because it consists of microscopic tubules that lead from the cortex to the renal 
papillae. The renal cortex dips into the medulla between the renal pyramids, forming renal 
columns and is surrounded by renal capsule. 
 
Fig 2: Structure of kidney 
 
Renal Blood Vessels 
The renal arteries, which arise from the abdominal aorta, supply blood to the kidneys.  
When a person is at rest, the renal arteries usually carry from 15% to 30% of the total cardiac 
output into the kidneys, although the kidneys account for only 1% of body weight. A renal 
artery enters a kidney through the hilum and gives off several branches, called the interlobar 
arteries, which pass between the renal pyramids. At the junction between the medulla and the 
cortex, the interlobar arteries branch to form a series of incomplete arches, the arcuate arteries  
which, in turn, give rise to interlobular arteries. The final branches of the interlobular arteries, 
called afferent arterioles lead to the nephrons, the functional units of the kidneys. Venous 
blood is returned through a series of vessels that generally correspond to the arterial 
pathways. 
 
Fig 3: Structure of Nephron and Juxta Glomerular apparatus  
Each kidney contains about one million functional units called nephrons, consists of a 
renal corpuscle and a renal tubule. A renal corpuscle consists of a filtering unit composed of a 
tangled cluster of blood capillaries called a glomerulus and a surrounding thin walled, sac 
like structure called a glomerular (Bowman′s) capsule. Afferent arterioles give rise to these 
capillaries, which lead to efferent arterioles. Filtration of fluid from the glomerular capillaries 
is the first step in urine formation. In the wall of the afferent arteriole near its attachment to 
the glomerulus, are large, vascular smooth muscle cells called juxtaglomerular cells. Together 
with the cells of the macula densa, they constitute the juxtaglomerular apparatus. 
 
The glomerular filtration rate (GFR) 
 
 
Fig 4: Factors effecting GFR 
 
 
The glomerular filtration rate (GFR) is directly proportional to the net filtration 
pressure. Consequently, the factors that affect the glomerular hydrostatic pressure, glomerular  
plasma osmotic pressure, or hydrostatic pressure in the glomerular capsule will also affect the 
rate of filtration. The glomerular hydrostatic pressure is the most important factor  
determining net filtration pressure and GFR. Since each glomerular capillary is located 
between two arterioles, the afferent and efferent arterioles, any change in the diameters of 
these vessels is likely to change glomerular hydrostatic pressure, changing glomerular  
filtration rate. The afferent arteriole, through which the blood enters the glomerulus, may 
vasoconstrict in response to stimulation by sympathetic nerve impulses. If this occurs, net  
filtration pressure in that glomerulus decreases, and filtration rate drops. If on the other  hand, 
the efferent arteriole through which the blood leaves the glomerulus vasoconstrict,  blood 
backs up into the glomerulus, net filtration pressure increases.  
 
The colloid osmotic pressure of the glomerular plasma also influences net filtration 
pressure and the rate of filtration. In other systemic capillaries, filtration occurs at the 
beginning of the capillary, but the osmotic effect of the plasma proteins predominates at the 
capillary and most filtered fluid is thus reabsorbed.  
 
At rest, the kidneys receive approximately 25% of the cardiac output, and about 20% 
of the blood plasma is filtered as it flows through the glomerular capillaries. This means that  
in an average adult, the glomerular filtration rate for the nephrons of both kidneys is about 
125 millilitres per minute. (6) 
 
 
 
 
Functions of the kidney 
The kidneys play a dominant role in regulating the composition and volume of the  
extracellular fluid (ECF). They normally maintain a stable internal environment by excreting 
in the urine appropriate amounts of many substances.  
The kidneys perform a variety of important functions: 
1. They regulate the osmotic pressure (osmolality) of the body fluids by excreting 
osmotically dilute or concentrated urine.  
2. They regulate the concentrations of numerous ions in blood plasma, including 
sodium, potassium, calcium, magnesium, chloride, bicarbonate, phosphate and 
sulfate. 
3. They play an essential role in acid–base balance by excreting H+ when there is excess 
acid or HCO3− when there is excess base. 
4. They regulate the volume of the ECF by controlling sodium and water excretion. 
5. They help regulate arterial blood pressure by adjusting sodium excretion and 
producing various substances (e.g., Renin) that can affect blood pressure.  
6. They eliminate the waste products of metabolism including urea, the main nitrogen 
containing end product of protein metabolism in humans, uric acid an end product of 
purine metabolism, and creatinine an end product of muscle metabolism.  
7. They remove many drugs (e.g., Penicillin) and foreign or toxic compounds.  
8. They are the major sites of production of certain hormones, including erythropoietin 
and 1, 25-dihydroxy vitamin D3. 
9. They degrade several polypeptide hormones, including insulin, glucagon, and 
parathyroid hormone. 
10. They synthesize ammonia, which plays a role in acid–base balance. (6) 
 
 
CHRONIC KIDNEY DISEASE 
Chronic kidney disease is a worldwide public health problem. It is the ninth leading 
cause of death. A trend towards increased incidence and prevalence is being reported  
worldwide with epidemic proportions in many countries.  
 
EPIDEMIOLOGY 
In United States, there is a rising incidence and prevalence of kidney failure with poor 
outcomes and high cost. The incidence of CKD is expected to rise annually by 5-8%. (7) The 
number of patients treated with dialysis or transplantation is projected to increase from 
almost 5, 00, 000 people in 2005 to 8, 00, 000 by 2020. A similar tendency is observed in 
Europe and United Kingdom. The estimated prevalence rates of chronic kidney disease in 
India are 800 and end-stage renal disease 200 per million inhabitants, respectively. (8) In 
South India, the main causes of CKD in decreasing order of prevalence are diabetic 
nephropathy (29.6%), chronic interstitial nephritis (20.4%), chronic glomerulonephritis 
(17.4%), and hypertensive nephropathy (11%). (9) Unfortunately chronic kidney disease is 
“under diagnosed” and “under-treated” resulting in lost opportunities for prevention. (10) 
The Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney 
Foundation (NKF) defines “Chronic Kidney Disease as either kidney damage or a glomerular 
filtration rate (GFR) of less than 60 mL/min/1.73 m2 for 3 or more months”. (11) In 2002; 
KDOQI published its classification of the stages of chronic kidney disease, as follows: 
Stage 1: Kidney damage with normal or increased GFR (>90 mL/min/1.73 m2) 
Stage 2: Mild reduction in GFR (60-89 mL/min/1.73 m2) 
Stage 3: Moderate reduction in GFR (30-59 mL/min/1.73 m2) 
Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2) 
Stage 5: Kidney failure (GFR < 15 mL/min/1.73 m2 or on dialysis). 
The KDOQI definition and classification of chronic kidney disease allow better  
communication among physicians and facilitate intervention at the different stages. Patients 
with chronic kidney disease stages 1-2 are generally asymptomatic; clinical manifestations 
typically appear in stages 3-5. 
 
Risk Factors for CKD 
According to KDOQI guidelines, the risk factors for the development of CKD can be  
divided into following: 
Susceptibility factors : There is increased susceptibility to kidney damage seen in older age, 
family history of chronic kidney disease, reduction in kidney mass and low birth weight. 
Initiation factors: They directly initiate kidney damage like Diabetes, high blood  pressure, 
autoimmune diseases, systemic infections, urinary tract infections, urinary stones, lower 
urinary tract obstruction and drug toxicity.  
Progression factors: They cause faster decline in kidney function after initiation of kidney 
damage they include higher level of proteinuria, higher blood pressure, poor glycaemic 
control in diabetes, smoking. 
End-stage factors: These factors increase morbidity and mortality patients they include  
lower dialysis dose (Kt/V), temporary vascular access, anaemia, low serum albumin level and 
late referral. (12) 
 
PATHOPHYSIOLOGY OF CKD 
Approximately 1 million nephrons are present in each kidney, contributing to the total 
GFR. In the case of renal injury, the kidney has an ability to maintain GFR, by methods  of 
hyperfiltration and compensatory hypertrophy of the remaining healthy nephrons. This, 
nephrons adaptability allows for continued normal clearance of plasma solutes. Plasma levels 
of substances such as urea and creatinine start to show significant increases only after total 
GFR has decreased to 50%. A rise in plasma creatinine from a baseline value of 0.6 mg/dL to 
1.2 mg/dL in a patient even though still within the reference range actually represents a loss 
of 50% of functioning nephron mass.  
 
Decreased renal function interferes with the kidneys ability to maintain fluid and 
electrolyte homeostasis. The ability to concentrate urine declines early and is followed by 
decrease in ability to excrete phosphate, acid, and potassium. When renal failure is advanced 
(GFR ≤ 10 mL/min/1.73 m2) the ability to dilute urine is lost; thus urine osmolality is usually 
fixed close to that of plasma (300 to 320 mOsm/kg) and urinary volume does not respond 
readily to variations in water intake. Plasma concentrations of creatinine and urea which are 
highly dependent on glomerular filtration begin a nonlinear rise as GFR diminishes. (13) 
 
Abnormalities of calcium, phosphate, parathyroid hormone (PTH), vitamin D 
metabolism and renal osteodystrophy can occur. Decreased renal production of calcitriol 
contributes to hypocalcemia. Decreased renal excretion of phosphate results in 
hyperphosphatemia. Secondary hyperparathyroidism is common and can develop in renal 
failure before abnormalities in calcium or phosphate concentrations occur. For this reason 
monitoring PTH levels in patients with moderate CKD is recommended even before 
hyperphosphatemia occurs. 
 
CKD - Clinical Features 
Lethargy, fatigue, anorexia, decreased mental acuity are commonly the earliest  
manifestations of renal failure. With more severe renal insufficiency neuromuscular  
symptoms may be present including coarse muscular twitches, peripheral sensory and motor 
neuropathies, muscle cramps, hyper reflexia, and seizures. Anorexia, nausea, vomiting, 
weight loss, stomatitis, unpleasant taste, discoloration of skin may be seen. Pruritus and under 
nutrition, leading to generalized tissue wasting are prominent features of CKD. 
Hypertension is present in more than 80% of patients with advanced CKD, usually 
related to hypervolemia, and occasionally due to activation of the Renin-Angiotensin-
Aldosterone System (RAAS). Heart failure caused by hypertension or coronary artery disease 
and renal retention of Na and water may lead to dependent edema. (13) 
 
Diagnosis 
Kidney damage is usually ascertained by markers rather than by kidney biopsy.  
According to the KDOQI, persistent proteinuria is the principal marker of kidney damage. (14) 
An elevated albumin– creatinine ratio in urine samples is usually considered abnormal. (15) (16) 
But, estimation of level of Glomerular filtration rate is the best measure of overall kidney 
functions both in health and disease. (17) The normal level of GFR varies according to age, sex 
and body mass. Normal GFR in young adults is approximately 120 to 130 mL/min per      
1.73 m2 and declines with age. (18) A GFR level less than 60 mL/min per 1.73 m2 represents 
loss of half or more of the adult level of normal kidney function. Below this level, the 
prevalence of complications of chronic kidney disease increases. Other markers of kidney 
damage include urinary sediments like WBCs and RBCs, abnormalities in electrolytes and 
urine osmolality, and abnormal findings on imaging studies. 
 
Estimation of GFR 
GFR was routinely measured using Creatinine clearance, but now various formulas 
have been developed for calculation of GFR, taking into account age, sex, race and body 
mass. The most commonly used equations are Cockcroft-Gault formula, the Modification of 
Diet in Renal Disease (MDRD) formula and CKD-EPI creatinine equation. 
 
Cockcroft–Gault equation (19): 
C Cr = (140 – Age) × Weight × 0.85 (if female) 
                72 × S Cr 
 
MDRD study equation (20): 
GFR (mL/min per 1.73 m2) = 186 × (S Cr) -1.154 × (age) -0.203 × 0.742 (if female) × 
1.210 (if African-American) 
 
CKD-EPI equation (21): 
GFR = 141 × min (S Cr/κ, 1) α × max (S Cr/κ, 1) -1.209 × 0.993 Age × 1.018 [if female] 
× 1.159 [if black] 
 
Here C Cr is creatinine clearance, S Cr is serum creatinine concentration in mg/dL, 
age is in years, and weight is in kg. κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of S Cr/κ or 1, and max indicates 
the maximum of S Cr/κ or 1 
The MDRD study equation has many advantages. It is more  accurate and precise than 
the Cockcroft–Gault equation for persons with a GFR less than approximately 90 mL/min per 
1.73 m2. The CKD-EPI creatinine equation is based on the same four variables as the MDRD 
Study equation, but uses a 2-slope spline to model the relationship between estimated GFR 
and serum creatinine, and a different relationship for age, sex and race. The equation was 
reported to perform better and with less bias than the MDRD Study equation, especially in 
patients with higher GFR. This results in reduced misclassification of CKD. The CKD-EPI 
creatinine equation is used in our study to estimate GFR.  
 
 
 
Complications of CKD 
1. Anaemia and coagulation disorders 
2. Bone disorders and osteoporosis 
3. Acidosis 
4. Cardiovascular complications 
5. Progression to end stage renal disease. 
Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) 
Definition of Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD): A 
systematic disorder of mineral and bone metabolism due to CKD manifested by either one or 
a combination of the following: 
1. Abnormalities of PTH, calcium, phosphorus, or vitamin D metabolism 
2. Abnormalities of bone turnover, mineralization, vo lume, linear growth or strength 
3. Vascular or other soft tissue calcification. (22) 
Mineral disturbances are common complications of CKD, beginning early in the 
course of disease. In stage 3 CKD, the kidney neither is able to fully excrete phosphorus load 
nor can convert vitamin D into its active metabolite calcitriol. This leads to a compensatory 
secondary hyperparathyroidism. (23) Elevated PTH and decreased calcitriol levels are found in 
40% of patients with stage 3 and 80% of patients with stage 4. (24) These minerals and 
endocrine functions disrupted in CKD are critically important in the regulation of bone 
remodelling. As a result, bone abnormalities like altered remodelling and loss of bone volume 
are found in almost all patients with CKD. (25) The skeletal changes result in an increased 
prevalence of hip fracture compared to the general population across the entire range of CKD 
stages 3-5 patients. (26) 
Derangements in mineral metabolism are also associated with cardiovascular disease 
and all-cause mortality.  (27) (28) (29) Cardiovascular disease accounts for 70% of all deaths in 
patients with CKD, with an overall mortality of 20% per year in patients on dialysis. In 
individuals with kidney failure on dialysis, cardiovascular mortality rates are 10 to 500 times 
higher than in the general population. (30)  Individuals at earlier stages of CKD not yet on 
dialysis (stages 3-4) have 17-times more chances to die of cardiovascular disease rather than 
progressing to dialysis. (31) 
Multiple cross-sectional studies in dialysis patients have found disordered mineral 
metabolism, including hyperphosphatemia and hyperparathyroidism, increasing the risk of 
cardiovascular and all-cause mortality. (32) (33) One mechanism by which abnormal mineral 
metabolism may increase cardiovascular risk is by inducing or accelerating arterial and 
valvular calcification. Patients on dialysis have 2 to 5 fold more coronary artery calcification 
than age-matched individuals with angiographically-proven coronary artery disease. (34) 
In patients not yet on dialysis, there is also increased coronary artery calcification 
compared to matched controls. (35) Peripheral artery calcification can lead to claudication and 
systolic hypertension; this in turn can leads to increased cardiac after load resistance and left 
ventricular hypertrophy. Coronary artery calcification can lead to cardiac ischemia and 
sudden death and this is the leading cause of cardiovascular death in patients on dialysis. (36) 
In patients with CKD, there is emerging evidence to support an interrelationship between 
bone, vascular disease and disordered mineral metabolism.  
These changes led to an initiative in 2006 by KDIGO to clarify and update 
nomenclature. As a result, the new term “Chronic Kidney Disease-Mineral and Bone 
Disorder (CKD-MBD)” was put forth to describe a clinical syndrome composed of mineral 
metabolism abnormalities, renal osteodystrophy and extra-osseous calcification including 
vascular calcification. 
A major component of CKD-MBD is vascular calcification, which is highly prevalent 
in CKD patients. Calcification can occur in intimal plaques and atheroma and also in the  
medial layer, especially in elastic containing arteries.  (37) (38) In patients starting on dialysis, 
60-70% of patients have significant coronary artery calcification by CT-based imaging. (39) 
Pathologically on autopsy studies, the medial layer of coronary arter ies is thicker in CKD 
patients than in controls, and medial coronary calcification is found in 20% of patients with 
CKD stages 4 and 5. (37) 
Calcification is also very common in the peripheral arteries; with demonstrating both 
intimal and medial calcification. (40) Both coronary artery and peripheral artery calcification 
are associated with increased mortality in patients on dialysis. The risk factors associated 
with arterial calcification include advanced age, diabetes, obesity, hypertension, 
dyslipidemia, inflammatory markers, hypoalbuminemia, use of calcium containing phosphate 
binders and disordered mineral metabolism. (41) Vascular calcification was previously thought 
to be a passive process, due to the elevations in calcium and phosphorus observed in patients 
with advanced CKD. Recent evidence confirms this is an active process due to a series of 
events. The initial step is thought to be a transformation or de-differentiation of vascular 
smooth muscle cells (VSMCs) to osteogenic or chondrogenic- like cells. These cells can then 
form matrix vesicles or apoptotic bodies that mineralize on an extracellular matrix, 
presumably in a manner similar to bone. 
The existence of abnormal bone remodelling in CKD may accelerate the process by 
providing excess calcium and phosphate for the matrix vesicles. The overall pathogenesis is 
regulated by a balance of pro-calcifying factors and inhibitors. Unfortunately in CKD, the 
procalcifying factors including hyperphosphatemia and hyperparathyroidism are common, 
and inhibitors such as fetuin-A and matrix GLA protein are reduced. 
 
 
 
 
 
 
PARATHYROID HORMONE 
 
Parathyroid Gland Anatomy 
The parathyroid glands were first described in 1850. Thirty years later, an illustrated 
anatomical and histological description in animals and humans was given by Ivar Sandstrom, 
a medical student from Uppsala. (42) In the 1980s, PTH was sequenced, its gene and its 
receptor were cloned and improved chemiluminescent immunoassays for intact PTH were  
developed. 
 
Structure of the Glands 
The parathyroid glands are small, yellowish-brown, ovoid or lentiform structures, 
lying between the posterior lobar borders of the thyroid gland and its capsule. They are 
commonly 6 mm long, 3-4 mm across, and 1-2 mm from back to front, each weighing about 
50mg, two on each side, superior and inferior. The parathyroid glands have a rich blood 
supply from the inferior thyroid arteries or from anastomoses between the superior and 
inferior vessels. (6) Parathyroid activity is controlled by variations in blood calcium level; it is 
inhibited by a rise and stimulated by a fall. (6) 
 
 
 
 
 
 
 
 
 
Biochemistry 
 
Fig 5: Structure of Parathyroid Hormone. 
PTH is an 84 amino acid peptide with a molecular weight of 9500 Da and a short half-
life of 2–3 min in the circulation. PTH binds to specific receptors on the membrane of target 
cells: renal & bone cells, fibroblasts, chondrocytes, vascular smooth muscle, adipocytes and 
placental trophoblasts. (43) 
 
PTH synthesis and degradation 
PTH is synthesized as a 115-amino acid polypeptide called pre-pro-PTH, which is 
cleaved within parathyroid cells at the N-terminal portion first to pro-PTH (90 amino acids) 
and then to PTH (84 amino acids). The latter is the major storage, secreted and biologically 
active form of the hormone. (44) Only the (1–34) amino acids fragments retain biological 
activity. The biosynthetic process is estimated to take less than one hour. The N-terminal 
cleaved pre-sequence is rich in hydrophobic amino acids that are necessary for transport into 
the endoplasmic reticulum, while the basic pro-peptide directs accurate cleavage of pro-PTH 
into the mature 1-84 molecule. The C-terminal portion of PTH is also essential for the PTH 
secretory process. PTH (1-84) is secreted by exocytosis within seconds after induction of 
hypocalcemia. (43) Calcium regulates not only the release but also the synthesis and 
degradation of PTH. Once secreted, PTH is rapidly cleared from plasma through uptake 
principally by the liver and kidney, where PTH 1-84 is cleaved into amino and carboxyl 
terminal fragments, which are then cleared by the kidney. (45) In CKD, amino-terminal 
fragments remain active and carboxy-terminal fragments accumulate.  
 
Mechanism of action of parathyroid hormone 
Physiological Role:  
The parathyroid glands are responsible for secreting PTH which maintains calcium 
homeostasis. PTH is a polypeptide hormone. Fluctuations in serum calcium concentration are 
detected by calcium receptors (CaR) which are G-protein coupled receptors located on the 
chief cells of the parathyroid gland that mediate the secretion of PTH. (46) Stimulated by low 
serum calcium levels, PTH secretion increases and up-regulates the expression of 1α-
hydroxylase in the kidney. This enzyme is responsible for the production of vitamin D or 
calcitriol. (47) 
Under hypocalcemic conditions, PTH stimulates the synthesis of calcitriol, correcting 
the calcium imbalance by  
1. Increasing absorption of calcium from the gastrointestinal tract 
2. Conserving calcium that would ordinarily be excreted by the kidneys  
3. Releasing calcium from bone. (48) 
Calcitriol and PTH are both capable of directly regulating serum mineral levels.  
 
 
The effects of PTH on the intestine are accomplished indirectly through the actions of 
calcitriol. Calcitriol has been shown to up-regulate the expression of calcium channel and 
transporter proteins, correcting hypocalcemia at the transcriptional level thus increases  
calcium absorption. (49) 
The effects of elevated PTH levels on the skeleton include the stimulation of calcium 
mobilization from bone and the direct regulation of osteoblasts apoptosis to correct  
hypocalcemia. (50) Completing the feedback loop, both elevated calcium and calcitriol levels 
can suppress PTH secretion but via different mechanisms. Sela-Brown et al have shown that 
calcitriol suppresses PTH synthesis at the transcriptional level whereas calcium regulation is 
post transcriptional. (51) Abnormalities in mineral homeostasis usually originate from the 
failure to maintain this critical feedback loop, often leading to  hyperparathyroidism. 
PTH is secreted by the parathyroid glands in response to hypocalcemia,  
hyperphosphatemia, and calcitriol deficiency. Minute-to-minute concentrations of PTH are 
most sensitive to low ionized calcium concentrations. The sensitivity of this response may be 
blunted in the presence of hyperphosphatemia in CKD. 
 
NORMAL FUNCTIONS OF PTH 
Effects of PTH on the kidney 
The distribution of PTH receptors and that of Ca2+ receptors overlap in the distal 
nephron, allowing calcium to have a direct effect on Ca2+ receptors and an indirect influence 
through modulation of plasma PTH concentrations on the renal component of calcium 
homeostasis. The intracellular mediator for PTH effects is intracellular cyclic adenosine 
monophosphate (cAMP), whose urinary secretion is a biochemical marker of PTH activity. 
 
 
 
The effects of PTH on the kidney include: 
(i) The major physiological effect of PTH is enhancement of Ca2+ reabsorption. This 
is due to effects on: the thick ascending loop of Henle it increases the 
transepithelial voltage gradient that drives passive Ca2+ transport. 
(ii) Increased phosphate excretion. PTH acts on the proximal and distal convoluted 
tubules and inhibits Na+ - dependent phosphate transport.  
(iii)  Increased bicarbonate clearance and alkalinisation of the urine result from 
inhibition of bicarbonate reabsorption in the proximal renal tubule. In patients 
with primary hyperparathyroidism, excessive secretion of PTH leads to a type of 
renal tubular acidosis. 
(iv)  Inhibition of Na+ reabsorption in the proximal tubule leads to an increase in Na+ 
loading of the distal tubule. Na+ is reabsorbed proportionally more than the 
associated water, leading to an increase in free water clearance. 
(v)  Increased activity of vitamin D1α hydroxylase.  
(vi)  In primary hyperparathyroidism, the renal effects of PTH are observed as 
hypercalciuria, hypophosphataemia, hyperchloremic acidosis, polyuria, 
polydypsia and an increased excretion of nephrogenous fraction of cAMP. 
 
Effects of PTH on the bone  
PTH produces both anabolic and catabolic effects which can be distinguished as early 
phase which includes mobilization of Ca2+ from bone in rapid equilibrium with the 
extracellular fluids and late phase increased by promoting reabsorption and bone remodelling. 
Osteoblasts are probably the primary bone cells that interact directly with PTH while 
osteoclasts seem to be devoid of PTH receptors. PTH inhibits osteoblasts and stimulates 
osteoclast mediated bone resorption, leading to an increase in alkaline phosphatase and 
increased urinary hydroxyproline. In primary hyperparathyroidism, changes in alkaline 
phosphatase and hydroxyproline are markers of bone disease.  
Effects of PTH on the intestine 
PTH does not directly affect gastrointestinal absorption of Ca2+. Its effects are 
mediated indirectly through regulation of synthesis of 1, 25(OH) 2 D3 in the kidney. 
Extracellular calcium 
Extracellular calcium is the major determinant of the rate of PTH secretion; slight 
reductions in calcium levels increase promptly the rate of PTH secretion. The initial changes 
in rate of PTH secretion in response to low calcium take place within seconds because of the 
release of preformed hormones from storage granules. Within 15–30 min, there is also an 
increase in the net rate of PTH synthesis. If the hypocalcaemic stimulus persists, modest 
increases in the amount of PTH mRNA take place early. Prolonged hypocalcaemia promotes 
parathyroid cellular hypertrophy and proliferation within days to weeks. The human Ca2+ 
receptor is encoded by a gene on chromosome 3q13-21 and consists of 1078 amino           
acids. (52) 
 
Calcium 
Serum calcium levels are controlled tightly in the range of 8.5-10.5 mg/dL. Total 
body stores are 1,000g among this 99% in bone, 0.9% intracellular, and 0.1% extracellular.  
Extracellular calcium is measured as total calcium: In this 50% is free, 10% is bound to  
anions and 40% is bound to albumin. Average dietary intake of calcium is 500- 1000mg/day. 
Calcium absorption occurs across intestinal epithelium through vitamin D-dependent 
transporters. Bioavailability of calcium from foods is altered by phytate and oxalate. 
Absorbed calcium enters into 3 compartments: Blood, soft tissue and bone. (53) 
 
 
Renal Handling of Calcium 
Reabsorption: 60-70% is reabsorbed passively in proximal tubules with sodium and  
water reabsorption. 10% is reabsorbed in the thick ascending limb. The rest is reabsorbed  
through transcellular pathways in the distal convoluted tubule, connecting tubule and cortical 
collecting duct. 
 
Calcium-Sensing Receptor (CaSR) 
It is a G-protein coupled protein that binds calcium and identifies even slight changes 
in ionized calcium levels; decreased ionized calcium stimulates PTH secretion. CaSR is  
expressed in parathyroid cells, thyroid C cells, intestine, kidney, and bone. In kidneys, CaSR 
is in mesangial cells and throughout tubules. Activation of CaSR on the thick ascending limb 
decreases paracellular calcium reabsorption. (53) 
Changes in concentrations of calcium is sensed by chief cells through a cell-surface, 
seven-transmembrane, G protein–coupled receptor, the CaSR (54) and receptor activity results 
in rapid alterations in PTH secretion. (55) After the induction of abrupt and sustained 
hypocalcemia, plasma concentrations of PTH increase within 1 minute, peak at 4 to 10 
minutes, and thereafter decline gradually to approximately 60% of the maximum at 60 
minutes, despite ongoing and constant hypocalcemia. Abrupt restoration of normocalcemia 
from the hypocalcemic state causes levels of PTH to decrease with an apparent half- life of 
approximately 3 minutes. In addition to its role in the parathyroid gland, the CaSR plays an 
important role in regulating calcium reabsorption in the thick ascending limb of the loop of 
Henle. (56) 
 
 
 
 
Phosphorus 
Serum phosphorus concentration ranges from 2.5-4.5 mg/dL; total-body stores of 
phosphorus equal 700 g. Of total-body stores, 85% is in bone as hydroxyapatite; 14% 
intracellular; and 1% extracellular. 
Diet contains about 1000-1400 mg/day of phosphorus; two-thirds excreted in urine, 
one third excreted in stool. Processed foods and foods rich in animal-based protein are high in 
Phosphorus and thus it is difficult for patients with CKD to control serum phosphorus levels 
by diet alone. 60-70% of dietary phosphorus is absorbed in all intestinal segments. (53) 
 
Renal Handling of Phosphorus 
Inorganic phosphorus is filtered by glomeruli, and then 70-80% is reabsorbed in proximal 
tubule through the Sodium-Phosphate co-transporter 2b. 20-30% of filtered phosphorus is 
reabsorbed in distal tubule. Renal phosphorus excretion is sensitive to serum phosphorus 
levels. PTH and Fibroblast Growth Factor 23 (FGF-23) increase phosphorus excretion.  
Phosphorus depletion decreases its own excretion. (53) 
 
Fibroblast Growth Factor 23 
It belongs to a group of molecules called phosphatonins. Phosphatonins are hormones 
that regulate phosphorus excretion. Three phosphatonins have been identified FGF-23 is one 
among them. They are produced almost exclusively in osteocytes and bone- lining cells, also 
found in heart, liver, thyroid, parathyroid, intestine and skeletal muscle. 
FGF-23 receptor on the proximal tubule requires a co-receptor (Klotho) for signal 
transduction. Klotho is found in the distal renal tubule and parathyroid gland. They are down-
regulated in aging and CKD. FGF-23 has the following actions down-regulates luminal 
sodium/phosphate co transporters in the proximal tubule, decreasing phosphorus reabsorption 
and therefore increasing its excretion. It Inhibits 1-hydroxylase, decreasing the conversion of 
25-hydroxyvitamin D to 1, 25-Dihydroxy vitamin D (calcitriol), it also inhibits PTH 
secretion. FGF-23 gene expression in bone is stimulated by elevated phosphorus, PTH and 
calcitriol levels. Both FGF-23 and PTH lead to increased phosphorus excretion.  
Hypocalcemia stimulates PTH and therefore in low calcium high-phosphorus states the action 
of PTH predominates where as in high-calcium high-phosphorus states, the action of FGF-23 
predominates. (53) 
 
Parathyroid hormone in Chronic Kidney Disease 
Pathophysiology 
PTH is associated significantly with mortality in observational studies at levels 
varying from 400-600 pg/mL, depending on the population analyzed. There are inconsistent 
data for the underlying bone histology by biopsy in dialysis patients for whom PTH levels  
were maintained in the range of 150-300 pg/mL recommended by KDOQI guidelines. Given 
these issues, recent KDIGO guidelines recommend extremes of risk for PTH at less than 2 
times the lower- limit and greater than 9 times the upper- limit values of the specific assay 
used. However, trends of PTH levels within that range should be evaluated and medications 
should be adjusted as needed. (53) 
 
Secondary hyperparathyroidism (SHPT) 
Secondary hyperparathyroidism describes a complex alteration in bone and mineral 
metabolism that occurs as a direct result of Chronic Kidney Disease (CKD). Patients with 
mild CKD may be asymptomatic and therefore may not be identified until the pathology of 
SHPT has begun. Identifying patients at risk and evaluating for SHPT is imperative because 
early intervention may slow or arrest the progression of both bone and cardiac disease. 
A common complication manifested in elevated parathyroid hormone (PTH) levels as 
a direct result of decreased renal function, vitamin D deficiency, and impaired mineral 
metabolism. (57) SHPT arises in most patients during the progression of CKD and is  
associated with several co morbidities, including renal osteodystrophy (ROD), extra skeletal 
calcification, and cardiovascular disease (CVD), resulting in increased mortality. (58)  
Several treatment options are available to slow the progression of CKD. A component 
of CKD care often overlooked and undertreated by both the primary care physician and the 
nephrologist is the management of SHPT, which can lead to CVD and ROD if untreated. 
Since kidney disease is often diagnosed comparatively late in many patients, the staging at 
diagnosis is often stage 3 or 4, the same time that these extra renal complications begin to 
appear. (59) (60) (61) Although hyperphosphatemia appears to be particularly important in the 
development of SHPT, the complication often occurs early in stage 3 of kidney failure, before 
the development of hyperphosphatemia. (62) (63) 
Hyperphosphatemia and an elevated Calcium X Phosphorous product, other 
widespread observational findings in CKD patients are considered to be independent risk 
factors for CVD, including hypertension, Left Ventricular Hypertrophy (LVH), increased 
serum creatinine levels, and microalbuminuria. (64) Traditional risk factors such as smoking, 
diabetes, hypertension, dyslipidemia, and obesity can be present at all stages of CKD and 
may also increase the risk of CVD. (65) 
 
Renal Osteodystrophy 
The processes of bone absorption and resorption are closely regulated in healthy 
individuals. ROD arises as a consequence of bone remodelling dysregulation. While the  
pathogenesis of ESRD is similar across patients, the pathogenesis of ROD varies from high-  
to low-bone turnover. Elevated levels of PTH stimulate bone demineralization and lead to 
high-bone turnover, a condition characterized by accelerated rates of bone absorption and 
resorption. The new bone is structurally inferior and fragile and carries an increased risk of 
fractures. The classic histological form of ROD is osteitis fibrosa, which arises from 
increased bone remodelling and fibrosis of the marrow. (66) 
 
Cardiovascular Disease 
The soft-tissue and vascular calcification that accompanies SHPT in advanced CKD is 
associated with a high risk of cardiac events. LVH is the most prevalent cardiac complication 
observed in CKD patients and is often associated with myocardial fibrosis, poor perfusion, 
and cell death. (67) (68) In a cross sectional study, Saleh et al found PTH to be an independent 
predictor of LVH among patients in the upper PTH percentiles. (69) Nasri et al. analyzed the 
influence of PTH on myocardial function. In their cross sectional study in hemodialysis 
patients, they determined that excess PTH played a significant role in the development of 
LVH and reduced left ventricular ejection fraction. (70) 
The relationship between elevated PTH and LVH was further explored in a 
retrospective study by Goto et al., who determined that parathyroidectomy in CKD patients 
with advanced SHPT led to a significant improvement of left ventricular ejection fraction and  
function. (71) A prospective study by Park et al. confirmed the association with SHPT, finding 
that PTH-suppressive calcitriol therapy led to a regression in myocardial hypertrophy in 
dialysis patients. (72) Hyperphosphatemia and hypercalcemia have been shown to promote  
calcification of the vasculature, myocardium, and cardiac valves. (73) (74) 
Vascular calcification, manifested in reduced vessel wall elasticity, increased intima 
media layer thickness and enhanced pulse-wave velocity, has been linked to LVH, and occurs 
with increased severity in dialysis patients versus non-CKD patients. (75) Vascular and soft-
tissue calcifications are strong predictors of cardiovascular mortality among                               
CKD patients. (76) 
The exact mechanism of calcification is not known but it is proposed that as the 
calcium, a divalent cation, and phosphorus, a monovalent anion, have a high binding affinity 
for each another. In serum, as the concentration of one or both ions increases, there is an 
increased risk for an ionic bond to form, creating an insoluble complex. This process may 
lead to extra skeletal calcification and potentially calciphylaxis or cardiac disease. (77) 
Additionally, the precipitation may decrease serum calcium concentrations, further  
stimulating PTH secretion. In fact, PTH production and secretion may be stimulated by 
hypocalcemia, hyperphosphatemia, and vitamin D deficiency. (78) Because PTH is chiefly 
responsible for preventing hypocalcemia, it stimulates osteoclasts to lyse bone, releasing 
calcium into the serum. 
Retrospective studies by Block et al and Ganesh et al suggest that hyperphosphatemia 
(> 6.5 mg/dL) and increased Calcium x Phosphorus product (>72 mg/dL) are factors that 
contribute to the high mortality rate in dialysis patients. (79) (80) 
 
CKD and Phosphorus 
Phosphorus homeostasis is impaired when the GFR is 60 mL/min as GFR decreases 
there is a gradual increase in serum phosphorus levels. During this period, normal phosphorus 
levels are maintained by continuous increases in FGF-23 and PTH levels. Eventually, this 
compensatory mechanism is overwhelmed when GFR decreases to 30 mL/min, and serum 
phosphorus levels may increase to higher than the reference range. Hyperphosphatemia also 
leads to inhibition of calcitriol synthesis, which stimulates further PTH production; together 
these processes trigger the development of secondary hyperparathyroidism in CKD. 
An observational data suggest that hyperphosphatemia is connected to increased 
morbidity and mortality in CKD. Various studies of patients with CKD stage 5, the 
phosphorus level associated with increased mortality varies from > 5.5 to > 7 mg/dL. Even in 
the non-CKD population, serum phosphorus level in the high-normal ranges is associated 
with increased risk of cardiovascular and all cause mortality. No interventional study has  
shown that decreasing phosphorus to a certain target level is associated with                             
better outcomes. (53) 
Calcium Abnormalities in CKD 
In CKD stages 2-3, serum calcium levels are maintained in the reference range at the 
cost of secondary elevations in PTH levels. Intestinal calcium absorption is impaired in CKD 
due to decreased calcitriol levels, but still proportional to calcium intake. Urinary calcium 
excretion decreases as CKD progresses due to PTH-associated increased reabsorption and 
decreased filtered fraction of calcium. In CKD, intestinal absorption is not equal to urinary 
excretion. The ability of bone to take up calcium depends on bone turnover. Patients with 
lower bone turnover (adynamic bone) are less able to take up calcium. When tubular 
excretion of calcium is decreased, these patients have a net positive calcium balance. Given a 
net positive calcium balance in late CKD, KDOQI guidelines recommend maximum total 
elemental calcium intake of 2 g/day. (53) 
Calcium Phosphorus product:  
Hyperphosphatemia is a common problem in patients with CKD has been associated 
with the progression of secondary hyperparathyroidism, deposition of calcium in soft tissues, 
and vascular calcification. (81) Higher serum PO4, Calcium X Phosphorus product is 
associated with increased coronary artery calcification. In addition to this, it also contributes 
to vascular smooth muscle cell proliferation and compromise flow in the coronary 
microcirculation. (82) (83) 
ABNORMALITIES OF BONE TURNOVER 
Chronic kidney disease is associated with a variety of bone disorders and disorders of 
calcium and phosphorus metabolism. The major disorders of bone are associated with high 
parathyroid hormone levels.  
 
 
Vascular and Soft Tissue Calcification 
In CKD extra skeletal calcification is highly prevalent. Vascular calcification 
prevalence in dialysis patients ranges from 50-90% in more than 20 studies that have 
addressed these using different modalities and is even present in children on dialysis therapy.  
Vascular calcification appears to start early in CKD and 50% of patients initiated on 
hemodialysis (HD) therapy already have evidence of coronary artery calcification (CAC).  
Age and dialysis vintage are consistently associated with coronary artery calcification. There 
are two types of vascular calcification: Intimal calcification - calcific plaques or 
circumferentially calcified atherosclerosis. Medial calcification is nonocclusive and leads to 
vascular stiffening; it can cause local ischemia and also affect the capacity of the vasculature 
to dampen increases in arterial pressure with each ventr icular systole, leading to left 
ventricular hypertrophy. 
Pathogenesis of vascular calcification:  
It features a phenotypic switch in which vascular smooth muscle cells (VSMCs) 
dedifferentiate to osteo/chondrocytic- like cells. The most important stimulus appears to be 
hyperphosphatemia, but others such as inflammation, cytokines, oxidative stress and 
advanced glycation end products also can enhance this transformation. Osteo/chondrocytic-
like cells lay down collagen and noncollagenous proteins in the intima or media. Calcium and 
phosphorus are incorporated into matrix vesicles to initiate mineralization in the form of 
hydroxyapatite. 
When the balance favours pro-mineralizing factors (e.g., elevations in calcium and  
phosphorus) over inhibitors of calcification (e.g., fetuin A, matrix GLA protein, osteopontin 
and pyrophosphate) calcification occurs. Patients with CKD who have low-turnover bone 
disease appear to have the greatest risk of vascular calcification. It is likely that adynamic  
bone is not able to take up high calcium loads and this excess calcium may become deposited 
in the vasculature. 
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4. MATERIALS AND METHODS 
 
Source of Data 
This study was duration based case control study, carried out for a period of six 
months on clinically confirmed cases of CKD visiting Nephrology OPD and in patients at 
Chennai Medical College Hospital & Research Centre, Irungalur. It also included 50 healthy 
controls visiting for regular health check-up. Both, males and females were included in the 
study. 
 
Inclusion Criteria: 
Patients in various stages of CKD (Age above 18years) 
 
Exclusion Criteria:  
Patients with autoimmune disorders,  
Post parathyroidectomy status patients. 
 
Collection of Sample: 
After obtaining approval from ethical committee and a written informed consent from 
both cases and controls, samples were collected. The baseline data, clinical history of both 
cases and controls were taken. The clinical findings, investigation report were entered on a 
predesigned proforma. 
Under strict aseptic precautions, 5ml of venous blood was collected after 8-10 hours 
of overnight fasting, from both cases and controls.  
 
 
 
Blood samples were collected in vaccutainer and kept at room temperature for 30-40 
minutes for clotting and then centrifuged at 3000 revolutions per minute for 10 minutes. 
Serum samples were separated and collected in an Eppendorf tube and following 
investigations were carried out.  
 
1) Intact PTH                           - Electrochemiluminescence immunoassay (ECLIA) 
2) Serum calcium  - Photometric test using arsenazo III 
3) Phosphorus   - Photometric UV test with endpoint determination                                                                                                                   
4) Blood urea   - GLDH method : Fully Enzymatic method  
5) Serum creatinine  - Modified Jaffe’s Method 
6) Alkaline Phosphatase - Kinetic photometric test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESTIMATION OF INTACT PTH 
Method 
Electrochemiluminescence immunoassay (ECLIA) method 
Principle: 
Sandwich principle. Total duration of assay: 18 minutes.  
▪ 1st incubation: 50 μL of sample, a biotinylated monoclonal PTH-specific antibody, 
and monoclonal PTH-specific antibody labeled with a ruthenium complex form a sandwich 
complex. 
▪ 2nd incubation: After addition of streptavidin-coated microparticles, the complex 
becomes bound to the solid phase via interaction of biotin and streptavidin. 
▪ The reaction mixture is aspirated into the measuring cell where the microparticles 
are magnetically captured onto the surface of the electrode. Unbound substances are then 
removed with ProCell/ProCell M. Application of a voltage to the electrode then induces  
chemiluminescent emission which is measured by a photomultiplier.  
▪ Results are determined via a calibration curve which is instrument specifically 
generated by 2-point calibration and a master curve provided via the reagent barcode. 
Reagents - working solutions 
The reagent rack pack is labeled as PTH. 
M  Streptavidin-coated microparticles (transparent cap), 1 bottle, 6.5 mL: 
Streptavidin-coated microparticles 0.72 mg/mL; preservative.  
R1  Anti-PTH-Ab~biotin (gray cap), 1 bottle, 7 mL: 
Biotinylated monoclonal anti-PTH antibody (mouse) 2.3 mg/L; 
Phosphate buffer 100 mmol/L, pH 7.0; preservative.  
R2  Anti-PTH-Ab~Ru(bpy) (black cap), 1 bottle, 7 mL: 
Monoclonal anti-PTH antibody (mouse) labeled with ruthenium complex 2.0 mg/L; 
phosphate buffer 100 mmol/L, pH 7.0; preservative. 
Reagent handling 
The reagents in the kit have been assembled into a ready for use unit that cannot be 
separated. All information required for correct operation is read in from the respective  
reagent barcodes. 
Storage and stability 
Store at 2-8 °C. 
Do not freeze. 
Store the Elecsys reagent kit upright in order to ensure complete availability of the 
microparticles during automatic mixing prior to use.  
Stability: 
Unopened at 2-8 °C:  Up to the stated expiration date 
After opening at 2-8 °C: 12 weeks 
On the analyzers:  8 weeks 
Specimen collection and preparation 
Only the specimens listed below were tested and found acceptable. 
Serum collected using standard sampling tubes.  
K2-EDTA and K3-EDTA plasma. 
Because of the short half life of PTH, it is recommended that, when serum is needed, 
the blood should be centrifuged immediately.  
Preference should be given to EDTA plasma, as it is stable longer than serum. 
Criterion: Method comparison serum versus plasma, slope 0.9-1.1 + intercept within < ± 2 x 
analytical sensitivity (LDL) + coefficient of correlation > 0.95. 
Serum: Stable for 8 hours at 15-25 °C, 2 days at 2-8 °C, 6 months at -20 °C. 
Plasma: Stable for 2 days at 15-25 °C, 3 days at 2-8 °C, 6 months at -20 °C. 
The sample types listed were tested with a selection of sample collection tubes that 
were commercially available at the time of testing, i.e. not all available tubes of all 
manufacturers were tested. Sample collection systems from various manufacturers may 
contain differing materials which could affect the test results in some cases. When processing 
samples in primary tubes (sample collection systems), follow the instructions of the tube 
manufacturer. 
Centrifuge samples containing precipitates before performing the assay.  
Do not use samples and controls stabilized with azide.  
Ensure the samples, calibrators and controls are at 20‑ 25 °C prior to measurement. 
Due to possible evaporation effects, samples, calibrators and controls on the analyzers 
should be analyzed / measured within 2 hours. 
Calibration 
Traceability: 
This method has been standardized against a commercial PTH test (RIA). The 
recovery of the NIBSC 95/646 (WHO) standard was assessed by testing dilutions in human 
serum covering the measuring range (40-4000 pg/mL) on 16 analyzers (cobas e 411 and 
cobas e 601 analyzers). The mean recovery was 100 % ± 4 %.  
Every Elecsys reagent set has a barcoded label containing specific information for 
calibration of the particular reagent lot. The predefined master curve is adapted to the 
analyzer using the relevant CalSet.  
Calibration frequency:  
Calibration must be performed once per reagent lot using fresh reagent (i.e. not more 
than 24 hours since the reagent kit was registered on the analyzer). Renewed calibration is 
recommended as follows: 
▪ After 12 weeks when using the same reagent lot 
▪ After 7 days (when using the same reagent kit on the analyzer)  
▪ As required: e.g. quality control findings outside the defined limits  
 
Quality control 
For quality control, use PreciControl Varia.  
In addition, other suitable control material can be used.  
Controls for the various concentration ranges should be run individually at least once 
every 24 hours when the test is in use, once per reagent kit, and following each calibration. 
The control intervals and limits should be adapted to each laboratory’s individual 
requirements. Values obtained should fall within the defined limits. Each laboratory should 
establish corrective measures to be taken if values fall outside the defined limits.  
 
Calculation 
The analyzer automatically calculates the analyte concentration of each sample (either 
in pg/mL or pmol/L). 
Conversion factors:  pg/mL x 0.106 = pmol/L 
pmol/L x 9.43 = pg/mL 
Limitations - interference 
The assay is unaffected by icterus (bilirubin < 1112 μmol/L or < 65 mg/dL), lipemia 
(Intralipid < 1500 mg/dL) and biotin (< 205 nmol/L or < 50 ng/mL).  
The assay is affected by hemolysis ≥ 0.15 g/dL. Do not analyze samples that show 
visible signs of hemolysis. 
Criterion: Recovery within ± 10 % of initial value.  
Samples should not be taken from patients receiving therapy with high biotin doses 
(i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. 
No interference was observed from rheumatoid factors up to a concentration of 1500 
IU/mL. 
There is no high-dose hook effect at PTH concentrations up to 17000 pg/mL (1802 
pmol/L). 
In vitro tests were performed on 16 commonly used pharmaceuticals. No interference 
with the assay was found. 
In rare cases, interference due to extremely high titers of antibodies to analyte-specific 
antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test 
design. 
For diagnostic purposes, the results should always be assessed in conjunction with the 
patient’s medical history, clinical examination and other findings. 
Limits and ranges 
Measuring range 
1.20-5000 pg/mL or 0.127-530 pmol/L (defined by the lower detection limit and the 
maximum of the master curve). Values below the lower detection limit are reported as < 1.20 
pg/mL (< 0.127 pmol/L). Values above the measuring range are reported as > 5000 pg/mL (> 
530 pmol/L). 
Lower limits of measurement 
Lower detection limit of the test 
Lower detection limit: 1.20 pg/mL (0.127 pmol/L) 
The lower detection limit represents the lowest measurable analyte level that can be 
distinguished from zero. It is calculated as the value lying two standard deviations above that 
of the lowest standard (master calibrator, standard 1 + 2 SD, repeatability study, n = 21).  
Dilution 
Not necessary due to the broad measuring range.  
Expected values 
15-65 pg/mL (1.6-6.9 pmol/L) (84) (85) 
 
 
 
ESTIMATION OF CALCIUM  
METHOD 
 Photometric test using arsenazo III 
PRINCIPLE 
 Calcium with arsenazo III at neutral pH yields a blue colored complex, whose 
intensity is proportional to the calcium concentration. Interference by magnesium is 
eliminated by addition of 8-hydroxyquinoline-5-sulfonic acid. 
REAGENTS 
Components and concentrations 
Reagent: 
Phosphate buffer  pH 7.5    50 mmol/L 
8-hydroxyquinoline-5-sulfonic acid   5 mmol/L 
Arsenazo III      120 µmol/L 
Standard      10 mg/dL (2.5 mmol/L) 
STORAGE INSTRUCTIONS AND REAGENT STABILITY 
The reagent is stable up to the end of the indicated month of expiry, if stored at 2-8 ̇ C  
and contamination is avoided. Do not freeze the reagent.  
The standard is stable up to the end of the indicated month of expiry, if stored at       
2-25 ̇ C. 
Reagent preparation 
The reagent and the standard are ready-to-use. 
Materials needed but not provided 
NaCl solution 9 g/L. 
General laboratory equipment.  
 
 
Specimen 
Serum, heparin plasma or urine 
Do not use EDTA plasma. 
Stability (86) 
in Serum/Plasma:  7 days at 20 - 25 °C 
3 weeks at 4 - 8 °C 
8 months at -20 °C 
Add 10 mL of concentrated HCl to 24 h urine and heat the specimen to dissolve 
calcium oxalate. 
Assay Procedure 
Wavelength    650 nm, Hg 623 nm (630 – 670 nm) 
Optical path    1 cm 
Temperature    20 – 25 °C / 37 °C 
Measurement    against reagent blank 
 
 Blank Sample / Standard 
Sample / Standard - 10 µl 
Dist. Water 10 µL - 
Reagent 1000 µl 1000 µl 
Mix, incubate for 5 minutes & read absorbance against reagent blank 
 
Calculation 
With standard or calibrator 
Calcium [mg/dL] =  A Sample      x   Conc. Std / Cal [mg/dL] 
         A Std / Cal 
 
CALIBRATORS AND CONTROLS:  
TruCal U 
TruLab N 
TruLab P 
Performance Characteristics 
Measuring range 
The test has been developed to determine calcium concentrations within a measuring range 
from 0.04 – 20 mg/dL (0.01 – 5 mmol/L). When values exceed this range samples should be 
diluted 1+1 with NaCl solution (9 g/L) and the result multiplied by 2.  
Specificity / Interferences 
No interference was observed by ascorbic acid up to 30 mg/dL, bilirubin up to 40 
mg/dL, hemoglobin up to 500 mg/dL, lipemia up to 2,000 mg/dL triglycerides and  
magnesium up to 15 mg/dL. Strontium salts in medicine may lead to strongly increased 
calcium values. 
Sensitivity / Limit of Detection 
The lower limit of detection is 0.04 mg/dL (0.01 mmol/L).  
 
Reference Range 
Serum/Plasma (87) : 8.6 – 10.3 mg/dL (2.15 – 2.57 mmol/L) 
 
 
 
 
 
 
 
ESTIMATION OF PHOSPHORUS 
METHOD 
Photometric UV test with endpoint determination 
PRINCIPLE 
Ammonium molybdate + Sulphuric acid + Phosphate  
 Inorg. Phosphorus molybdate complex 
Maximum complex absorption is at 340 nm. 
REAGENTS 
Components and concentrations 
R1: Glycine/sulphuric acid buffer    50 mmol/L 
R2: Glycine buffer      50 mmol/L 
 Ammonium molybdate    1.75 mmol/L 
Standard (Phosphorus):     5 mg/dL (1.61 mmol/L)  
REAGENT STORAGE AND STABILITY 
The reagents and standard are stable up to the end of the indicated month of expiry, if 
stored at 2-8 ̇ C  and contamination is avoided. Do not freeze the reagents.  
Reagent preparation 
The reagent and the standard are ready-to-use. 
Materials needed but not supplied with reagent kit 
NaCl solution 9 g/L. 
General laboratory equipment.  
Specimen 
Serum, heparin plasma or urine 
Stability in serum/plasma: 1 day at 20 – 25 °C 
4 days at 4 – 8 °C 
1 year at -20 °C 
Assay Procedure 
Wavelength     340 nm, Hg 334 nm, Hg 365 nm 
660 nm bichromatic 
Optical path     1 cm 
Temperature     20 - 25 °C/37 °C 
Measurement     Against reagent blank 
SUBSTARTE START PROCEDURE: 
SAMPLE START PROCEDURE:      
 Blank Sample / Standard 
Sample / Standard - 10 µl 
Dist. Water 10 µL - 
Monoreagent 1000 µl 1000 µl 
Mix, incubate 5 minutes., read absorbance against reagent blank within 60 minutes. Calculate 
the absorbance difference: 
ΔA =  A Sample / Standard 
 Blank Sample / Standard 
Sample / Standard - 10 µL 
Dist. Water 10 µL - 
Reagent 1 800 µL 800 µL 
Mix, incubate 5 minutes., read absorbance A1, then add: 
Reagent 2 200µL 200µL 
Mix, read absorbance A2 within 5 - 60 minutes. Calculate the absorbance difference: 
ΔA = [(A2 – A1) Sample / Standard] 
Calculation 
With standard or calibrator 
Phosphorus [mg/dL] =  ΔA Sample      x   Conc. Std / Cal [mg/dL] 
          ΔA Std / Cal 
 
CALIBRATORS AND CONTROLS:  
TruCal U 
TruLab N 
TruLab P 
TruLab Urine Level 1 
TruLab Urine Level 2 
Performance Characteristics 
Measuring range 
The test has been developed to determine phosphorus concentrations within a 
measuring range from 0.2– 30 mg/dL (0.065 – 9.69 mmol/L). When values exceed this range 
samples should be diluted 1 + 10 with NaCl solution (9 g/L) and the result multiplied by 11.  
Specificity/Interferences 
No interference was observed by ascorbic acid up to 30 mg/dL, bilirubin up to 60 
mg/dL, hemoglobin up to 1000 mg/dL and lipemia up to 2000 mg/dL triglycerides.  Please be 
aware that ditaurobilirubin interferes from the concentration 3 mg/dL on, when phosphate is 
measured on systems which are unable to handle a second wavelength. For further 
information on interfering substances refer to Young DS [5].  
Sensitivity/Limit of Detection 
The lower limit of detection is 0.2 mg/dL (0.065 mmol/L).  
Reference Range 
Serum/Plasma (88):  Adults 2.6 - 4.5 mg/dL 
 
ESTIMATION OF BLOOD UREA 
 
METHOD 
 Glutamate Dehydrogenase (GLDH) method : Fully Enzymatic method  
 
PRINCIPLE 
Urea + 2 H2O       ----Urease---  2 NH4
+   +  Co3
2- 
 
2-Oxoglutarate  +  NH4
+  + NADH  ----GLDH---    L-glutamate  +  H2O  +  NAD
+ 
 
CONTENTS 
ENZ 8  x  40 ml Enzymes 
 Tris buffer  (pH 7.8)   125 mmol/L 
ADP      0.88 mmol/L 
Urease      ≥ 20 kU/L 
GLDH      ≥ 0.3 kU/L 
Sodium Azide     0.095 % 
SUB 8  x  10 ml Substrate 
 2-Oxoglutarate      25 mmol/L 
 NADH      1.25 mmol/L 
Sodium Azide     0.095 % 
STD    1  x  3 ml Standard 
            Urea      80 mg/dL (13.3 mmol/L) 
Sodium Azide     0.095 % 
 
 
REAGENT PREPARATION 
 The reagents are ready for use and can directly be applied on automated analyzers 
(Reagent start procedure).  
 For sample start procedure working reagent is prepared by mixing 4 parts of ENZ 
with 1 part of SUB; e.g. 40 ml ENZ + 10 ml SUB 
 
REAGENT STORAGE AND STABILITY 
The individual reagents are stable, even after opening, up to the end of the indicated 
month of expiry, if stored at 2-8 ̇ C  and contamination is avoided.  
The working reagent is stable for 5 days at 15-25 ̇ C  and for 4 weeks at 2-8 ̇ C. 
 
SPECIMEN 
Serum, plasma (except ammonium heparinate plasma) 
Stability (89) 
In serum/plasma:  7 days at 20 – 25 °C 
1 year at -20 °C 
 
Assay 
Wavelength    340 nm, Hg 334 nm, 365nm 
Optical path    1 cm 
Temperature    25° C, 30° C or 37° C 
Measurement    Against reagent blank 
 
 
 
 
PROCEDURE: 
Reagent Start Procedure     
 
SAMPLE START PROCEDURE:      
 Reagent blank (RB) Sample / Standard 
Sample / Standard - 10 µl 
Working reagent 1000 µl 1000 µl 
Mix, read absorbance of Sample / Standard after 30 seconds (A1), and read again after exactly 
1 minute (A2). Calculate the absorbance difference: 
ΔA Sample / Standard = (A2-A1) - ΔARB. 
 
CALCULATION: 
Serum, Plasma  
                         C = 80.0 × ΔA Sample / ΔA Standard [mg/dL]  
     or 
                         C = 13.3 × ΔA Sample / ΔA Standard [mmol/L] 
 
 Reagent Blank (RB) Sample / Standard 
Sample / Standard - 10 µL 
Enzyme  1000 µL 1000 µL 
Mix, incubate for approximately for 1 minute. 
Substrate 250µL 250µL 
Mix, read absorbance of Sample / Standard after 30 seconds (A1) and read after exactly 1 
minute (A2). Calculate the absorbance difference: 
ΔA Sample / Standard = (A2-A1) - ΔARB. 
LINEARITY: 
The test is linear up to 300 mg/dL or 50 mmol/L.  
 
REFERENCE VALUES: 
Serum (90):  10 - 50 mg / dL   or  1.7 - 8.3 mmol / L 
 
QUALITY CONTROL 
 All control sera with urea values determined by this method can be employed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESTIMATION OF CREATININE 
METHOD 
Kinetic test without deproteinization according to Jaffe method  
Principle 
 Creatinine forms a colored orange-red complex in an alkaline picrate solution. The 
difference in absorbance at fixed times during conversion is proportional to the concentration 
of creatinine in the sample. 
Creatinine  +  Picric acid    Creatinine picrate complex 
REAGENTS 
Components and concentrations 
R1: Sodium hydroxide     0.2 mol/L 
R2: Picric acid      20 mmol/L 
Standard:       2 mg/dL (177 µmol/L)  
REAGENT STORAGE AND STABILITY 
The reagents and standard are stable up to the end of the indicated month of expiry, if 
stored at 2-25 ̇ C  and contamination is avoided. Do not freeze the reagents and 
protect from direct light. 
Reagent preparation 
The standard is ready-to-use. 
Substrate start 
The reagents are ready-to-use. 
Sample start 
Mix 4 parts of R1  +  1 part of R2; 
Stability: 5 hours at 15 - 25 ̇ C 
 
 
Materials needed but not supplied with reagent kit 
NaCl solution 9 g/L. 
General laboratory equipment.  
Specimen 
Serum, heparin plasma, urine 
Stability 
In serum / plasma:  7 days at 4-25°C 
at least 3 months at -20°C 
Assay Procedure 
Wavelength    Hg 492 nm, (490 - 510 nm) 
Optical path    1 cm 
Temperature    20 - 25 °C / 37 °C 
Measurement    Against reagent blank 
PROCEDURE: 
SUBSTARTE START PROCEDURE: 
 Blank Sample / Standard 
Sample / Standard - 50 µL 
Dist. Water 50 µL - 
Reagent 1 1000 µL 1000 µL 
Mix, incubate 0-5 minute., then add: 
Reagent 2 250µL 250µL 
Mix, read absorbance after 60 seconds (A1) and read after further 2 minutes (A2). Calculate 
the absorbance difference: 
ΔA = [(A2 – A1) sample or standard] - [(A2 – A1) blank] 
SAMPLE START PROCEDURE:      
 Blank Sample / Standard 
Sample / Standard - 50 µl 
Dist. Water 50 µL - 
Monoreagent 1000 µl 1000 µl 
Mix, read absorbance after 60 seconds (A1) and read after further 2 minutes (A2). Calculate 
the absorbance difference: 
ΔA = [(A2 – A1) sample or standard] - [(A2 – A1) blank] 
 
Calculation 
With standard or calibrator 
Serum/Plasma 
 
Creatinine [mg / dL] = ΔA Sample / ΔA Standard / Cal    x   Conc. Std /Cal [mg / dL] 
 
CALIBRATORS AND CONTROLS:  
TruCal U 
TruLab N 
TruLab P 
TruLab Urine Level 1 
TruLab Urine Level 2 
Performance Characteristics 
Measuring range 
The test has been developed to determine creatinine concentrations within a 
measuring range from 0.2 – 15 mg/dL (18 – 1330 μmol/L). When values exceed this range 
samples should be diluted 1 + 1 with NaCl solution (9 g/L) and the result multiplied by 2.  
 
Sensitivity/Limit of Detection 
The lower limit of detection is 0.2 mg/dL. 
Specificity/Interferences 
No interference was observed by ascorbic acid up to 30 mg/dL, hemoglobin up to 500 
mg/dL and lipemia up to 2,000 mg/dL triglycerides. Bilirubin interferes starting with a 
bilirubin concentration of 4 mg/dL. 
 
Reference Range (91) 
Men:   0.7 – 1.2 mg/dL 
Women:  0.5 – 0.9 mg/dL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ESTIMATION OF ALKALINE PHOSPHATASE 
METHOD 
Kinetic photometric test 
PRINCIPLE 
p-Nitrophenylphosphate  +  H2O    ----AP  Phosphate  + p-Nitrophenol 
REAGENTS 
Components and concentrations 
R1: 2-Amino-2-methyl-1-propanol   pH 10.4 1.1mol/L 
 Magnesium acetate     2 mmol/L 
 Zinc sulphate      0.5 mmol/L 
 HEDTA      2.5 mmol/L 
R2: p-Nitrophenylphosphate    80 mmol/L  
REAGENT STORAGE AND STABILITY 
The reagents and standard are stable up to the end of the indicated month of expiry, if 
stored at 2-8 ̇ C  and contamination is avoided. Do not freeze the reagents and reagent 2 must 
be protected from light. 
Materials needed but not supplied with reagent kit 
NaCl solution 9 g/L. 
General laboratory equipment.  
Reagent preparation 
Substrate start 
The reagents are ready-to-use. 
Sample start 
Mix 4 parts of R1 + 1 part of R2; 
Stability: 5 days at 15 - 25 ̇ C; 4 weeks at 2 - 8 ̇ C; 
    The monoreagent must be protected from light.  
Specimen 
Serum or heparin plasma. Do not use hemolytic samples.  
Stability (92):  7 days at 4 – 8 °C 
2 months at - 20 °C 
Assay Procedure 
Wavelength    Hg 405 nm, (400 – 420 nm) 
Optical path    1 cm 
Temperature    37 °C 
Measurement    Against reagent blank 
SUBSTARTE START PROCEDURE: 
SAMPLE START PROCEDURE:      
 Blank Sample or Calibrator 
Sample or Calibrator - 20 µl 
Dist. Water 20 µL - 
Monoreagent 1000 µl 1000 µl 
Mix, read absorbance after 1 minute and read again after 1, 2 & 3 minutes. 
 
 Blank Sample or Calibrator 
Sample or Calibrator - 20 µL 
Dist. Water 20 µL - 
Reagent 1 1000 µL 1000 µL 
Mix, incubate for 1 minute., then add: 
Reagent 2 250µL 250µL 
Mix, read absorbance after 1 minute and read again after 1, 2 & 3 minutes. 
Calculation 
With factor 
From absorbance readings calculate ΔA/min and multiply by the corresponding factor 
from table below: 
ΔA/min x factor = AP activity [U/L] 
Substrate start   405 nm   3433 
Sample start    405 nm   2757 
With calibrator 
AP [U/L]  =  ΔA / min Sample x Conc. Calibrator [U/L] 
                               ΔA / min Calibrator 
Calculation factor 
ALP [U/L] x 0.0167 = ALP [μkat/L] 
 
CALIBRATORS AND CONTROLS:  
TruCal U 
TruLab N 
TruLab P 
 
Performance characteristics 
Measuring range 
On automated systems the test is suitable for the determination of AP activities up to 
1400 U/L. In case of a manual procedure, the test is suitable for AP  activities which 
correspond to a maximum of ΔA/min of 0.25. If such values are exceeded the samples should 
be diluted 1 + 9 with NaCl solution (9 g/L) and results multiplied by 10. 
 
 
Specificity/Interferences (93) 
No interference was observed by ascorbic acid up to 30 mg/dL, conjugated bilirubin 
up to 60 mg/dL, unconjugated bilirubin to 25 mg/dL, hemoglobin up to 100 mg/dL and 
lipemia up to 2000 mg/dL triglycerides. 
 
Sensitivity/Limit of Detection 
The lower limit of detection is 2 U/L.  
 
Reference Range (94) 
Men  :  40 – 130 [U/L] 
Women :  35 – 105 [U/L] 
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5. RESULTS 
Statistical Methods: 
Descriptive and inferential statistical analysis has been carried out in the present 
study. Results on continuous measurements are presented on Mean±SD (Min-Max) and 
results on categorical measurements are presented in Number (%).  Significance is assessed at 
5 % level of significance. The following assumptions on data are made; Assumptions: 1. 
Dependent variables should be normally distributed, 2. Samples drawn from the population 
should be random, and 3. Cases of the samples should be independent. 
Analysis of variance (ANOVA) has been used to find the significance of study 
parameters between three or more groups of patients, Student test  (two tailed, independent) 
has been used to find the significance of study parameters on continuous scale between two 
groups Inter group analysis) on metric parameters. Leven1s test for homogeneity of variance 
has been performed to assess the homogeneity of variance. Chi square/Fisher Exact test has 
been used to find the significance of study parameters on categorical scale between two or 
more groups. (95) (96) (97) (98) 
 
Significant figures 
** Strongly significant (P value: P ≤ 0.01) 
*   Moderately significant (P value: 0.01 < P ≤ 0.05) 
+   Suggestive significance (P value: 0.05 <P < 0.10) 
 
Statistical analysis: Data were analysed using SPSS 20.0.; Microsoft word and Excel have 
been used to generate graphs, tables. 
 
 
In our study of role of intact parathyroid hormone and other biochemical parameters 
in early diagnosis of mineral disturbances in patients with Chronic Kidney Disease, the 
following results were obtained for 50 cases and 50 controls. Comparison of biochemical 
parameters in two groups studied was as follows; 
 
The table below summarizes the findings, which are elaborated later on. 
 
 
Table 1: Comparison of bio chemical parameters in cases and controls 
 
 
 
 
 
 
 Table 2: Age distribution in cases and controls 
Samples were age matched. 
 
Fig 6: Age distribution in cases and controls 
Samples were matched according to their age. Maximum number of patients, 32% 
were in the age group of 51-60 years, followed by 24% patients in 31-40 years. The mean age 
in cases is 47.26 ±12.73 years, whereas in controls mean age is 43.83 ±15.12 years. 
  
Table 3: Gender distribution in cases and controls studied 
 
 
  
Fig 7: Gender distribution in cases and controls studied 
 
Samples are gender matched. 70% of cases are males and 30% are females. In 
controls 62% are males and 38% are females.  
 
 
 
 
 
Distribution of PTH in two groups studied 
Parathyroid hormone levels were compared in both cases and controls. The mean 
level of PTH in cases is 136.80 ±92.70 where as in controls mean PTH level is 52.47 ±16.34 
pg/mL. Statistically significant increase in levels of PTH were seen in patients than 
controls (P<0.001). 
 
Table 4: Distribution of PTH in two groups studied 
 
Fig 8: Distribution of PTH in two groups studied 
Distribution of Urea in two groups studied 
Urea levels were measured in cases and controls. The normal reference range of urea 
is 18-46 mg/dL. 52% of patients in CKD had urea levels above 46 mg/dL, none of the 
controls had urea levels above 46 mg/dL. 
36% of patients and 74% of controls had urea levels between 18-46 mg/dL. 26% of 
controls and 12% of cases had urea levels <18 mg/dL. 
 
Table 5: Distribution of Urea in two groups studied 
 
 
Fig 9: Distribution of Urea in two groups studied 
Distribution of Creatinine in two groups studied 
Creatinine levels were measured in cases and controls. The normal reference range for 
creatinine is between 0.6-1.2 mg/dL. 54% of cases had Creatinine levels >1.2mg/dL and none 
of the controls were in this range, 46% of case had Creatinine levels between 0.6-1.2 mg/dL 
and 48% of controls had the values in same range. 52% of controls had levels less <0.6 
mg/dL and none of cases had within this range.  
 
Table 6: Distribution of Creatinine in two groups studied 
 
 
Fig 10: Distribution of Creatinine in two groups studied 
 
Distribution of Calcium in two groups studied 
Calcium levels were compared in cases and controls.  The normal reference range of 
calcium is 8.5-10.2 mg/dL. 51.9% of cases had calcium levels between 8.5-10.2 mg/dL and 
76% of controls had within the same range where as 48.1% of cases and only 24% of controls  
had levels <8.5 mg/dL. 
 
Table 7: Distribution of Calcium in two groups studied 
 
 
Fig 11: Distribution of Calcium in two groups studied 
 
 
 
Distribution of Phosphorus in two groups studied 
Phosphorus levels were measured in cases and controls. The normal reference range 
of Phosphorus is 2.5-4.5 mg/dL. 62% of cases had Phosphorus levels between 2.5-4.5mg/dL 
and 98% of controls.20% of cases had levels between 4.6-5.5 mg/dL only 2% of controls had 
in same range. 18% of patients had levels >5.5 mg/dL and none of controls had in this range.  
 
Table 8: Distribution of Phosphorus in two groups studied 
 
Fig 12: Distribution of Phosphorus in two groups studied 
Distribution of Alkaline Phosphatase in two groups studied 
Alkaline Phosphatase levels were measured in cases and controls. The normal range is  
56-153 IU/L. 94% of patients had alkaline phosphatase levels between 56-153 IU/L where as 
98% of controls had in the same range. 6% of cases had levels >153 IU/L and only 2% of 
controls had in the same range. 
 
Table 9: Distribution of Alkaline Phosphatase in two groups studied 
 
 
Fig 13: Distribution of Alkaline Phosphatase in two groups studied 
 
 
Graphical representation of the findings 
This is a table showing the mean levels of PTH, Urea, Creatinine, Calcium, 
Phosphorus and Alkaline phosphatase levels in cases and controls.  
 
Table 10: Comparison of mean levels of biochemical parameters in cases and controls 
 
 
Fig 14: Mean PTH levels in cases and controls 
The mean levels of PTH in cases are 136.80±92.70 and controls are 52.47±16.34 
pg/ml. There is a statistically significant increase in PTH levels in cases as compared to 
controls; p value is <0.001. 
 Fig 15: Mean Urea levels in cases and controls 
Statistically significant increase in urea levels was seen in cases as compared to 
controls (p<0.001). The mean level in cases is 76.60±69.77 and control is 223.50± 7.46 
(p<0.001). 
 
Fig 16: Mean Creatinine levels in cases and controls 
Statistically significant increase in creatinine levels was seen in cases as compared to 
controls. The mean level in cases is 4.11±4.25 and control is 0.56±0.10 (p<0.001). 
 Fig 17: Mean Calcium levels in cases and controls. 
Statistically significant increase in levels of calcium was seen in cases as compared to 
controls. The mean level of calcium in cases is 8.35±1.07 and control is 8.98±0.98 (p<0.001). 
 
Fig 18: Mean Phosphorus levels in cases and controls 
 
Increase in levels of phosphorus was observed in cases as compared to controls 
which was statistically significant. The mean level of phosphorus in cases is 4.40±1.70 and  
control is 3.47±0.62 (p<0.001). 
 Fig 19: Mean Alkaline Phosphatase levels in cases and controls. 
 
There is elevation in Alkaline Phosphatase levels in cases as compared to controls 
but the increase was not statistically significant. The mean level in cases is 90.92±46.37 and  
control is 82.91± 21.78 (p=0.285). 
 
 
 
 
 
 
 
 
 
 
Distribution of cases in various stages of CKD were as follows  
There were totally 50 cases; they were divided into various stages depending upon 
eGFR. 38% of patients were in CKD stage 5, followed by 36% in stage 2, 10% patients in 
stage 4 and 8% of patients were present in stage 1 and 3 respectively. 
 
Table 11: Distribution of cases in various stages of CKD 
 
Fig 20: Distribution of cases in various stages of CKD 
 
 
The levels of PTH, Calcium and phosphorus of patients in various stages of CKD 
are as follows : 
 
In stage I CKD, we found that the levels of PTH, calcium and phosphorus were 
within normal range. 
 
 
In stage II CKD, the levels of PTH and phosphorus were slightly elevated; but within 
the reference range and calcium levels were also normal.  
 
 
In stage III, there is marginal elevation in PTH and phosphorus levels; and fall in 
calcium levels. 
 
 
 
 
In stage IV CKD, there is further elevation in PTH and phosphorus levels; and 
calcium levels come back to within range. 
 
 
In stage V CKD, there is significant increase in PTH levels,  moderate increase in 
phosphorus levels and fall in calcium levels.  
 
 
The level of PTH, calcium and phosphorus are compared with various stages of CKD. 
 
 
Table 12: Values of PTH, Ca and P in different stages of CKD 
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6. DISCUSSION 
Many studies and literature have shown that CKD is associated with alterations in 
calcium and phosphorus metabolism leading to increased mortality and morbidity. These 
alterations would cause changes in PTH levels in almost all stages of disease. We have used 
this in our study to find out the usefulness of the Elevated PTH levels as an early marker of 
derangements in bone and mineral metabolism associated with CKD. (99) 
Nephrology guidelines also recommend targets and early treatment strategies to 
correct serum levels of phosphorus, calcium, and parathyroid hormone, because many data 
suggested there was a clear association between these potential risk biomarkers and vascular 
disease and death. (2) So numerous drugs including phosphorus binders, vitamin D and 
calcimimetic agents have been specifically developed and promoted to decrease these 
complications. 
 
Pattern of Parathyroid hormone levels in CKD 
Recent observational studies have shown that even a slight elevation in PTH levels 
has been associated with an increased cardiovascular risk. It is also found that monitoring 
PTH levels from the early stages of CKD can prevent complications due to mineral 
disturbances. 
Elevated serum phosphorus has been associated with the progression of secondary 
hyperparathyroidism and deposition of calcium in soft tissues.  
The long-term consequences associated with persistently elevated PTH levels in CKD 
include high-turnover bone disease, anemia, CVD, and mortality. (2) As a result, both NKF 
and Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend that PTH 
levels should be regularly monitored beginning in stage 3 CKD and that elevated levels 
should be treated with a combination of dietary phosphorus restriction and therapy with 
vitamin D and/or calcimimetic. (100) 
In our study, we found a statistically significant increase in PTH level in cases as  
compared to controls (p < 0.001). The findings are similar to Block et al study, a significant 
increase in PTH levels was observed in CKD. They also identified high PTH levels as a 
significant correlate of all-cause mortality. They concluded that elevations in serum PTH 
might be associated with increased risk of death from cardiac causes. (79) 
Amann K et al studies also implicated parathyroid hormone as a permissive factor 
that promotes cardiac fibroblast activation and intermyocardiocytic fibrosis. (101) 
Wald et al, Tentori et al and Kalantar-Zadeh et al studies also observed a 
significant increase in PTH levels in CKD. 
Phosphorus and Calcium in CKD : 
Elevated serum phosphorus has been related to vascular & coronary artery 
calcification and resulting cardiovascular morbidity and mortality. Among mineral 
abnormalities; hyperphosphatemia is most prevalent among patients with ESRD. 
Shanthi K et al studies have found that a significant increase in serum phosphorus 
levels in patients in CKD, (82) which is similar to that of our study. We observed a statistically 
significant increase in serum phosphorus levels in cases as compared to controls (p < 0.001). 
Hyperphosphatemia and hypercalcemia have been shown to promote calcification of 
the vasculature, myocardium and cardiac valves. (74) Vascular calcification, manifested in 
reduced vessel wall elasticity, increased intima-media layer thickness and enhanced pulse-
wave velocity, has been linked to LVH and occurs with increased severity in dialysis patients 
versus non-CKD patients. (102) 
Craver et al studies observed a significant increase in phosphorus levels in patients 
who were in various stages of CKD (p < 0.001). He found that elevated PTH levels were 
associated with increased cardiovascular risk, loss of arterial elasticity and left  ventricular 
hypertrophy. Relevant mechanism could be direct action on vascular and cardiac cells, which 
express PTH receptors. 
J. Floege et al reported a significant increase in phosphorus levels and concluded that  
high level of phosphorus is a significant risk factor for mortality in CKD. (103) 
Goodman et al in a resent observational study highlighted the increased prevalence 
and extent of coronary artery calcification in young dialysis patients compared with normal 
controls. (104) 
Serum calcium levels are also involved in hyperparathyroidism progression but are 
more likely to play an important role in advanced stages, when they begin to decrease.  
Schwartz et al studies showed an association between higher levels of serum phosphorus and 
calcium-phosphorus product with an unfavourable renal outcome.(105) In their study higher 
serum phosphorus was associated with significantly higher risk for progression of CKD, even 
after adjustment for multiple potential confounders. The association of higher serum 
phosphorus with progressive CKD was more accentuated in patients with higher serum 
calcium. Thus supporting the hypothesis that tissue calcification may be the reason behind the 
complications. Tissue calcification is involved at the cellular and sub cellular levels, with 
hyperphosphatemia shown to be associated with increased expression of osteoblasts specific 
proteins in vascular smooth muscle cells (VSMCs). (106) 
Reynolds et al showed that higher ambient serum calcium level led to more 
significant phosphorus-driven calcification of vascular smooth muscle in vitro. (107) 
Rise in urea and creatinine levels are seen, which are used to support the diagnosis 
of CKD. 
In our study, increase in alkaline phosphatase levels was observed in cases as 
compared to controls and the rise was of significant only in stage 5. 
High serum alkaline phosphatase is associated with increased mortality. An analysis 
of the Dialysis Outcomes and Practice Patterns Study (DOPPS) database found that elevated  
serum alkaline phosphatase levels in hemodialysis patients were associated with higher risk 
of hospitalization and death. 
The potential mechanisms for this observation remain unclear. A study by Lee et al 
concluded that, alkaline phosphatase can promote vascular calcification by hydrolyzing 
pyrophosphate in the arterial wall. (108) 
Sigrist et al conducted a longitudinal study and found elevated levels of alkaline  
phosphatase in stage IV and V of CKD, they found that higher levels of serum alkaline  
phosphatase were associated with progressive arterial calcification. (109) 
For early diagnosis, staging of CKD is required and was done by CKD-EPI 
equation and the levels of PTH, Calcium and Phosphorus of patients in various stages of 
CKD are as follows; 
 In stage I CKD, we found that the levels of PTH, calcium and phosphorus were  
within normal range. 
 In stage II CKD, the levels of PTH and phosphorus were slightly elevated, but within 
the reference range; and calcium levels were also normal.  
 In stage III CKD, there is marginal elevation in PTH and phosphorus levels; and fall 
in calcium levels. 
 In stage IV CKD, there is further elevation in PTH and phosphorus levels; and 
calcium levels come back to within range. 
 In stage V CKD, there is significant increase in PTH levels; moderate increase in 
phosphorus levels and fall in calcium levels. 
The findings are concordant with National Kidney Foundation’s Kidney Early 
Evaluation Program (KEEP) study. (110) They observed a statistically significant increase in 
PTH, calcium & phosphorus levels in various stages of CKD. They found a signific ant 
decrease in levels of calcium from stage III to stage IV; whereas in stage V, it is again raised. 
Similar findings were observed in our study, where the levels of calcium is normal in stage I 
and II; the levels fall in stage III and come back to normal range in stage IV and V. 
Kates DM et al, studies evaluated the relationships among serum phosphate, calcium,  
PTH and 1, 25-dihydroxyvitamin D in CKD patients who were in various stages of disease 
and demonstrated a similar finding. The study also suggested that phosphate may directly 
enhance PTH secretion in this setting. (111) 
Levin et al performed a cross-sectional analysis and found that calcium and 
phosphorus values did not become abnormal and were relatively stable until stage IV     
CKD. (112)  In our study we observed an increase in phosphorus levels from Stage III of CKD.  
Until recently, it was thought that hyperphosphatemia was the earliest sign of SHPT 
and bone metabolism disorders. However, when patients reach Stage 3 CKD, it is highly  
probable that none of the routine biochemical parameters assessed will be abnormal. Infact, 
the PTH level is often increased before clinical hyperphosphatemia occurs.  
Patel S et al, performed a cross-sectional study and observed that PTH levels 
increased with worsening of CKD. (113) A significant increase in PTH levels were also 
observed in our study which further increased with progression of CKD.  
Levin A et al performed a cohort study in patients with stage 4–5 CKD and found 
that the levels of PTH and phosphorus were associated with an increased risk of death and the  
progression of renal failure, whereas vitamin D therapy was associated with better        
survival. (114) 
Similar results indicating that secondary hyperparathyroidism is a risk factor 
associated with progression to dialysis or death have been obtained in cohort study conducted 
by Schumock CKD patients. (115) 
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7. CONCLUSION 
The aim of our study was to correlate serum intact parathyroid hormone, urea, 
creatinine, calcium, phosphorus, alkaline phosphatase in patients with CKD and to compare it 
with controls and to know the role of parathyroid hormone in early diagnosis of mineral 
disturbances. 
In our study, we found that statistically significant increase in the serum levels of 
intact parathyroid hormone, urea,  creatinine, calcium and phosphorus, in patients with CKD 
as compared with controls. There was an increase in alkaline phosphatase level between cases 
and controls, but was not statistically significant. A statistically significant increase in PTH 
levels from stage III of CKD was also observed when calcium and phosphorus were still 
within normal range. Thus PTH levels can be used as a marker to identify the mineral 
disturbances in early stages of CKD. 
Like in the standard guidelines which highlight the importance of measuring PTH 
early in the course of disease recommends an annual measurement of PTH once the  diagnosis 
of CKD is made. If the PTH levels are measured and maintained within the target range, 
many complications can be prevented. 
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PROFORMA  
Name: Mr/Mrs.                                                     Age:      Years; Sex: M / F ;  IP/OP No: 
Address:      Occupation: 
Ht:  Cms; Wt:  Kgs; BMI: 
 
Complaints with H/O. Present illness:       
 
H/O. Past illness: 
 
Treatment History: 
 
Duration of CKD/Stage: 
 
Personal History: Smoking-            ;   Alcohol-               ;   Diet- Veg / Non Veg 
 
Family History: ( Diabetes / Hypertension / CAD / Thyroid disease ) 
  
O/E: Pulse-  / min ; B.P-     mmHg       
S/E: CVS-   ; RS-   ; PA-    ; CNS- 
Investigations: 
Urea ( mg/dL )  
Creatinine ( mg/dL )  
eGFR ( mL/mt/1.73m
2 
)  
Calcium ( mg/dL )  
Phosphorus ( mg/dL )  
Alkaline Phosphatase (U/L)  
Intact PTH ( pg/mL )  
 
 
 
CONSENT FORM - ENGLISH 
 
 
 
 
CONSENT FORM - TAMIL 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
